Retrospective analysis of factors influencing immunologic failure among people living with HIV on antiretroviral therapy.

IF 1.2 4区医学 Q4 HEALTH POLICY & SERVICES

Aids Care-Psychological and Socio-Medical Aspects of Aids/hiv Pub Date : 2025-09-01 Epub Date: 2025-07-28 DOI:10.1080/09540121.2025.2534541

Donglan Chen, Qiuhua Chen, Manzhou Lin

{"title":"Retrospective analysis of factors influencing immunologic failure among people living with HIV on antiretroviral therapy.","authors":"Donglan Chen, Qiuhua Chen, Manzhou Lin","doi":"10.1080/09540121.2025.2534541","DOIUrl":null,"url":null,"abstract":"A retrospective analysis was performed on 98 people living with HIV-1 (PLHIV) undergoing antiretroviral therapy (ART) between July 2019 and July 2023. The incidence of poor CD4+ T cell recovery was 27.55% (27/98), while the immunologic reconstruction success rate was 72.45% (71/98). Multivariate logistic regression analysis confirmed 5 independent high-risk factors for treatment failure: age ≥ 60 years (β = 1.473, OR = 4.364, 95% CI = 1.614-11.799, P = 0.004), injection drug use (β = 1.792, OR = 6.000, 95% CI = 1.030-34.936, P = 0.046), co-infection (β = 1.530, OR = 4.620, 95% CI = 1.321-16.157, P = 0.017), time from diagnosis-to-treatment initiation ≥ 12 months (β = 1.348, OR = 3.850, 95% CI = 1.236-11.992, P = 0.020), and baseline CD4+ T cells count < 200 /μL (β = 2.071, OR = 7.934, 95% CI = 2.915-21.594, P = 0.000).","PeriodicalId":48370,"journal":{"name":"Aids Care-Psychological and Socio-Medical Aspects of Aids/hiv","volume":" ","pages":"1475-1481"},"PeriodicalIF":1.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aids Care-Psychological and Socio-Medical Aspects of Aids/hiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09540121.2025.2534541","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

A retrospective analysis was performed on 98 people living with HIV-1 (PLHIV) undergoing antiretroviral therapy (ART) between July 2019 and July 2023. The incidence of poor CD4+ T cell recovery was 27.55% (27/98), while the immunologic reconstruction success rate was 72.45% (71/98). Multivariate logistic regression analysis confirmed 5 independent high-risk factors for treatment failure: age ≥ 60 years (β = 1.473, OR = 4.364, 95% CI = 1.614-11.799, P = 0.004), injection drug use (β = 1.792, OR = 6.000, 95% CI = 1.030-34.936, P = 0.046), co-infection (β = 1.530, OR = 4.620, 95% CI = 1.321-16.157, P = 0.017), time from diagnosis-to-treatment initiation ≥ 12 months (β = 1.348, OR = 3.850, 95% CI = 1.236-11.992, P = 0.020), and baseline CD4+ T cells count < 200 /μL (β = 2.071, OR = 7.934, 95% CI = 2.915-21.594, P = 0.000).

查看原文本刊更多论文

艾滋病病毒感染者抗逆转录病毒治疗免疫功能衰竭影响因素的回顾性分析。

对2019年7月至2023年7月期间接受抗逆转录病毒治疗（ART）的98名HIV-1 （PLHIV）感染者进行了回顾性分析。CD4+ T细胞恢复不良发生率为27.55%(27/98)，免疫重建成功率为72.45%（71/98）。多元逻辑回归分析证实5治疗失败的独立高危因素:年龄≥60岁(β= 1.473,= 4.364,95% CI -11.799 = 1.614, P = 0.004),注射毒品(β= 1.792,= 6.000,95% CI -34.936 = 1.030, P = 0.046),合并感染(β= 1.530,= 4.620,95% CI -16.157 = 1.321, P = 0.017),时间从diagnosis-to-treatment起始≥12个月(β= 1.348,= 3.850,95% CI -11.992 = 1.236, P = 0.020),和基准CD4 + T细胞计数P = 0.000)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aids Care-Psychological and Socio-Medical Aspects of Aids/hiv Multiple-

CiteScore

3.50

自引率

0.00%

发文量

172